Physician

Robert W Hostoffer, DO

According to 2025 Medicare claims, Robert Hostoffer, DO (NPI: 1730159674) practices pediatric medicine in the Cleveland, OH market, with the plurality of this provider's patient population coming from Cuyahoga, OH. This provider's primary affiliated billing organization is ALLERGY IMMUNOLOGY ASSOCIATES INC (NPI: 1922212760; TIN: 34-1151148) and primary practice location at 44124-4034.

Hostoffer's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 310 traditional Medicare patients, billed 121,268 HCPCS/CPT codes, and received $7,489,747 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,954 prescription claims across 378 beneficiaries totaling $7,215,721 in drug costs, led by Berinert (C1 Esterase Inhibitor). DME data shows 421 claims. Open Payments data shows 184 records totaling $4,067. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $1,481,113 to $7,489,747. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $3,804,858 and ending at $7,215,721. In contrast, DME billing represents a smaller volume and moved from a lower plateau to a higher plateau, from $3,915 to $10,164.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	274	51,249	$1,481,113
2016	316	47,497	$1,354,279
2017	336	77,196	$1,740,581
2018	312	82,550	$1,913,265
2019	358	69,147	$2,029,069
2020	379	89,607	$2,295,174
2021	365	91,768	$2,568,855
2022	384	106,670	$3,576,653
2023	338	110,874	$4,923,480
2024	310	121,268	$7,489,747

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	286	2,475	$3,804,858
2016	277	2,460	$6,121,916
2017	286	2,658	$8,003,795
2018	284	2,478	$7,325,363
2019	298	2,549	$1,507,187
2020	347	2,639	$3,496,856
2021	353	2,518	$6,264,731
2022	364	2,769	$6,885,216
2023	357	2,814	$6,765,846
2024	378	2,954	$7,215,721

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	161	$168,433
2016	N/R	191	$317,143
2017	N/R	145	$230,309
2018	N/R	119	$185,149
2019	N/R	148	$212,193
2020	N/R	135	$231,244
2021	N/R	272	$309,244
2022	N/R	297	$284,758
2023	N/R	425	$443,877
2024	N/R	421	$505,691

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	204	399	$90
J1556	Injection, immune globulin (bivigam), 500 mg	51	51,932	$58
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	68	809	$42
96366	Infusion into a vein for therapy, prevention, or diagnosis, each additional hour	66	1,725	$14
96160	Administration and interpretation of patient-focused health risk assessment	48	65	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Berinert	C1 Esterase Inhibitor	16	408	$3,706,185
Haegarda	C1 Esterase Inhibitor	13	364	$1,083,062
Takhzyro	Lanadelumab-Flyo	12	336	$633,779
Icatibant	Icatibant Acetate	14	398	$633,539
Firazyr	Icatibant Acetate	14	420	$474,469

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	46	$182,794
J1555	Injection, immune globulin (cuvitru), 100 mg	N	N/R	22	$158,625
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	N	N/R	23	$79,778
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	N	N/R	22	$38,352
J1459	Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	11	$29,170

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	184	$4,067	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Robert W. Hostoffer, DO?

Tedicare shows public-source Medicare data for Robert W. Hostoffer, DO (NPI 1730159674), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Robert W. Hostoffer, DO have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Robert W. Hostoffer, DO?

Robert W. Hostoffer, DO is linked to ALLERGY IMMUNOLOGY ASSOCIATES INC (billing NPI 1922212760) in the available physician profile data.

Does Robert W. Hostoffer, DO have Open Payments data?

Robert W. Hostoffer, DO has 184 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.